The incidence and outcome of photodynamic therapy for macular degeneration in the Northern region of the UK

Eye

Volumn 18, Issue 6, 2004, Pages 588-594

  Talks, S James ^a   Setty, R ^a   Clarke, L ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Age related macular degeneration; Incidence; Outcome; Photodynamic therapy

Indexed keywords

ADULT; AGED; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NATIONAL HEALTH SERVICE; PHOTODYNAMIC THERAPY; POPULATION RESEARCH; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY;

EID: 3242692514     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700709     Document Type: Review

References (21)

1. Taylor HR, Keefe JE. World blindness: a 21st century perspective. Br J Ophthalmol 2001; 85: 261-266.
2. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: one-year results of 2 randomised clinical trials-TAP report 1. Arch Ophthalmol 1999; 117: 1329-1345.
3. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two year results of 2 randomised clinical trials-TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
4. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of vereporfin photodynamic therapy Br J Ophthalmol 2001; 85: 483-495.
5. Macular photocoagulation study group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol 1991; 109: 1242-1257.
6. Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
7. Bressler NM, Gills JP. Age related macular degeneration, new hope for a common problem comes from photodynamic therapy. Br Med J 2000; 321: 1425-1427.
8. Mandal N, Chisholm IH. Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalomol 2002; 86: 118-119.
9. Kahn HA, Leibowitz HM, Ganley JP, Kini M M, Colton T, Nickerson RS et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106: 17-32.
10. Martinez GS, Campbell AJ, Reinken J, Allan BC. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol 1982; 94: 181-189.
11. Dickinson AJ, Sparrow JM, Duke AM, Thompson JR, Gibson JM, Rosenthal AR. Prevalence of age-related maculopathy at two points in time in an elderly British population. Eye 1997; 11: 301-314.
12. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver Dam Eye Study Ophthalmology 1992; 99: 933-943.
13. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study Ophthalmology 1995; 102: 1450-1460.
14. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF et al. The prevalence of age-related maculopathy in the Rotterdam Study Ophthalmology 1995; 102: 205-210.
15. Pagliarini S, Moramarco A, Wormald RPL, Piguet B, Carresi C, Balacco-Gabrieli C et al. Age-related macular disease in rural Southern Italy Arch Ophthalmol 1997; 115: 616-622.
16. Klein R, Klein BEK, Cruickshanks KJ. The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res 1999; 18: 371-389.
17. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin and its potential impact on retinal practices. Retina 2000; 20: 325-330.
18. Huddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002; 86: 663-669.
19. Grey RB, Bird AC, Chisholm IH. Senile disciform macular degeneration. Features indicating suitability for photocoagulation. Br J Ophthalmol 1979; 63: 85-89.
20. Kaiser RS, Berger JW, William AG, Tolentino MJ, Maguire AM, Alexander J et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age related macular degeneration. Retina 2002; 22: 683-690.
21. Harding S. Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal. Eye 2003; 17: 119-121.